98%
921
2 minutes
20
Alopecia areata (AA) is an autoimmune hair loss condition that is difficult to treat and frequently disruptive to the psychosocial well-being of patients. Platelet-rich plasma (PRP) is an innovative therapy that provides concentrated GFs that impart anti-inflammatory effects. Optical coherence tomography (OCT) is a noninvasive imaging modality with the potential for providing quantitative monitoring of AA response to PRP. Our objective is to share our experience using OCT to monitor the therapeutic progress of patients with AA treated with PRP. Two patients with patchy AA and one with alopecia universalis were treated with PRP three times at 6-week intervals as part of a larger clinical trial. Patients were followed from baseline to week 24 with OCT imaging. OCT demonstrates an increase in hair density associated with improvement in inflammation at week 24. Conversely, the patient with alopecia universalis did not experience any significant change in follicular activity. This case series exemplifies the potential of PRP in inflammatory regulation as well as hair regrowth in patchy AA, whereas there is no notable advantage in alopecia universalis. Our findings add evidence on the possible value of OCT in quantitatively assessing hair growth progress throughout a treatment course.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jisp.2020.05.008 | DOI Listing |
J Dermatolog Treat
December 2025
Department of Dermatology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Objectives: Baricitinib showed efficacy for alopecia areata (AA) in clinical trials, with real-world data supporting its short-term effectiveness. However, long-term data are limited. We assessed the effectiveness and safety of baricitinib in AA patients over one year and explored predictive factors.
View Article and Find Full Text PDFJ Drugs Dermatol
September 2025
Background: Alopecia universalis (AU) is the most severe form of alopecia areata (AA), characterized by complete scalp and body hair loss. While post-COVID-19 hair loss is often attributed to telogen effluvium (TE), emerging evidence suggests that COVID-19 may also trigger AU through immune dysregulation, particularly via interferon-gamma (IFN-γ)-mediated inflammation. The chronic and relapsing nature of AU raises challenges in long-term disease management, particularly regarding treatment duration and relapse prevention.
View Article and Find Full Text PDFFront Immunol
August 2025
Department of Dermatology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Background: Alopecia areata (AA) is a common autoimmune disorder causing patchy hair loss. Epidemiological observations and molecular studies collectively suggest an underrecognized interplay between AA and cardiovascular disease (CVD). However, the relationship between them remains controversial and requires further investigation.
View Article and Find Full Text PDFJAAD Case Rep
September 2025
Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Front Med (Lausanne)
July 2025
Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Background: Alopecia areata (AA) is a chronic immune-mediated disorder causing non-scarring hair loss. Severe forms like alopecia totalis (AT) and alopecia universalis (AU) pose therapeutic difficult situations. Topical immunotherapy with squaric acid dibutylester (SADBE) and diphenylcyclopropenone (DPCP) is widely used but has variable efficacy.
View Article and Find Full Text PDF